ClinicalTrials.gg
CompletedNCT01071122Updated Jan 27, 2014

FOCUS (Nifedipine GITS's Effect on Central Pressure Assessed by Applanation Tonometry)

A Phase 4 interventional study of Nifedipine (Adalat, BAYA1040) and Valsartan and Nifedipine (Adalat, BAYA1040) in Hypertension, sponsored by Bayer. Completed at 15 sites in Korea, Republic of. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-01-27.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
365
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies testing nifedipine in Hypertension — 3 open to participants now, 3 under way, 1 of them phase 3. Nifedipine · Hypertension.

Enrollment
5th of 29
365 · median 72
Started
2010
with 2 others
Phase 4
12 of 29
1 open now
Registered
8th of 29
by date
Lead sponsor
11 of 29
Bayer

Among the 29 studies testing nifedipine in Hypertension, this one is the 5th largest by enrollment, is one of 3 that started in 2010, is one of 12 in phase 4, and was the 8th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

3 of the 29 studies testing nifedipine in Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nifedipine

Nifedipine: first FDA approval 1981 (PROCARDIA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing nifedipine in Hypertension, or all of them as a file.
02

Study summary

To determine whether the combination of nifedipine GITS and valsartan is more effective in reducing central blood pressure than nifedipine GITS or valsartan alone, and to determine whether nifedipine GITS is comparable to valsartan

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Central blood pressure
  • Nifedipine
  • Valsartan
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Untreated grade 2 or grade 3 hypertension defined by mean diastolic blood pressure (BP) >/= 100 and/or mean systolic BP >/= 160mmHg without anti-hypertensive treatment or Treated grade 2 hypertension defined by mean diastolic BP >/= 100 and/or mean systolic BP >/=160mmHg with current diuretics and/or beta-blockers use for >/= 4 weeks

Exclusion criteria

Exclusion Criteria:

  • Secondary form of hypertension
  • Mean systolic BP >/= 200mmHg and or mean diastolic BP >/= 120mmHg
  • Treated with other antihypertensive medication except diuretics or beta-blockers
  • Type 1 diabetes mellitus
  • Known cardiovascular disease including history of angina pectoris, heart failure, history of myocardial infarction or revascularization procedure, or cerebrovascular disease (including stroke and ) within the previous 12 months
  • Renal insufficiency defined as a serum creatinine: >/= 1.7 mg/dl
  • Pregnancy or not using in childbearing aged women
  • Breast feeding women
  • Any disease or condition that in the opinion of the investigator may interfere with completion of the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
365 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Nifedipine (Adalat, BAYA1040) and Valsartan

  • Active comparator
    Arm 2

    Drug: Nifedipine (Adalat, BAYA1040)

  • Active comparator
    Arm 3

    Drug: Valsartan

Interventions

06

What researchers measure

Primary outcomes

  1. Central systolic blood pressure

    Time frame: Week 8

Secondary outcomes

  1. Change in central diastolic blood pressure and pulse pressure

    Time frame: Week 4,8

  2. Change in central systolic blood pressure

    Time frame: Week 4

  3. Change in brachial systolic blood pressure and diastolic blood pressure

    Time frame: Week 4,8

  4. Change in brachial pulse pressure

    Time frame: Week4,8

  5. Change in augmentation index and augmentation pressure

    Time frame: Week 4,8

  6. Response rate(≥10 mmHg decrease of brachial SBP and ≥5mmHg decrease of brachial DBP)

    Time frame: Week 4,8

  7. Control rate (≤140/90 mmHg, 130/80 mmHg for diabetes, of brachial BP

    Time frame: Week 4,8

07

Study locations

15 sites
  • Goyang-si, Gyeonggido 411-706, Korea, Republic of
  • Goyang, Gyeonggido 410-773, Korea, Republic of
  • Chungchungbuk-do, Korea 361-711, Korea, Republic of
  • Seoul, Korea 135-720, Korea, Republic of
  • Seoul, Seoul Teugbyeolsi 152-703, Korea, Republic of
  • Busan, Korea, Republic of
  • Gwangju, 501-757, Korea, Republic of
  • Joong-gu, 100-380, Korea, Republic of
  • Kungki-do, 463-707, Korea, Republic of
  • Seoul, 110-744, Korea, Republic of
  • Seoul, 120-752, Korea, Republic of
  • Seoul, 135-710, Korea, Republic of
  • Seoul, 136-705, Korea, Republic of
  • Seoul, 137-701, Korea, Republic of
  • Suwan, 443-721, Korea, Republic of
08

References and documents

Publications

  • Park JB, Shin JH, Kim DS, Youn HJ, Park SW, Shim WJ, Park CG, Kim DW, Lee HY, Choi DJ, Rim SJ, Lee SY, Kim JH; FOCUS Investigators. Safety of the Up-titration of Nifedipine GITS and Valsartan or Low-dose Combination in Uncontrolled Hypertension: the FOCUS Study. Clin Ther. 2016 Apr;38(4):832-42. doi: 10.1016/j.clinthera.2016.02.025. Epub 2016 Mar 17. PubMed 26996246 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2010
First posted
Feb 19, 2010
Start
Jan 2010
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Last update
Jan 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01071122
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Feb 19, 2010
Start date
Jan 2010
Primary completion
Feb 2012
Completion
Feb 2012
Last update
Jan 27, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nifedipine · Valsartan

Start the discussion